Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis

Tor Christian Aase Johannessen, Joydeep Mukherjee, Pavithra Viswanath, Shigeo Oba, Sabrina M. Ronen, Rolf Bjerkvig, Russell O. Pieper

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Missense mutations in the active site of isocitrate dehydrogenase 1 (IDH1) biologically and diagnostically distinguish low-grade gliomas and secondary glioblastomas from primary glioblastomas. IDH1 mutations lead to the formation of the oncometabolite 2-hydroxyglutarate (2-HG) from the reduction of a-ketoglutarate (a-KG), which in turn facilitates tumorigenesis by modifying DNA and histone methylation as well blocking differentiation processes. Although mutant IDH1 expression is thought to drive the gliomagenesis process, the extent to which it remains a viable therapeutic target remains unknown. To address this question, we exposed immortalized (p53/pRb deficient), untransformed human astrocytes to the mutant IDH1 inhibitor AGI-5198 prior to, concomitant with, or at intervals after, introduction of transforming mutant IDH1, then measured effects on 2-HG levels, histone methylation (H3K4me3, H3K9me2, H3K9me3, or H3K27me3), and growth in soft agar. Addition of AGI-5198 prior to, or concomitant with, introduction of mutant IDH1 blocked all mutant IDH1-driven changes, including cellular transformation. Addition at time intervals as short as 4 days following introduction of mutant IDH1 also suppressed 2-HG levels, but had minimal effects on histone methylation, and lost the ability to suppress clonogenicity in a time-dependent manner. Furthermore, in two different models of mutant IDH1-driven gliomagenesis, AGI-5198 exposures that abolished production of 2-HG also failed to decrease histone methylation, adherent cell growth, or anchorage-independent growth in soft agar over a prolonged period. These studies show although mutant IDH1 expression drives gliomagenesis, mutant IDH1 itself rapidly converts from driver to passenger. Implications: Agents that target mutant IDH may be effective for a narrow time and may require further optimization or additional therapeutics in glioma.

Original languageEnglish
Pages (from-to)976-983
Number of pages8
JournalMolecular Cancer Research
Volume14
Issue number10
DOIs
Publication statusPublished - 01-10-2016

Fingerprint

Isocitrate Dehydrogenase
Histones
Methylation
Glioblastoma
Glioma
Agar
Growth
Missense Mutation
DNA Methylation
Astrocytes
Catalytic Domain
Carcinogenesis

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Johannessen, T. C. A., Mukherjee, J., Viswanath, P., Oba, S., Ronen, S. M., Bjerkvig, R., & Pieper, R. O. (2016). Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis. Molecular Cancer Research, 14(10), 976-983. https://doi.org/10.1158/1541-7786.MCR-16-0141
Johannessen, Tor Christian Aase ; Mukherjee, Joydeep ; Viswanath, Pavithra ; Oba, Shigeo ; Ronen, Sabrina M. ; Bjerkvig, Rolf ; Pieper, Russell O. / Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis. In: Molecular Cancer Research. 2016 ; Vol. 14, No. 10. pp. 976-983.
@article{d36ad1d7dc3b48cf897cdcf17681d5c6,
title = "Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis",
abstract = "Missense mutations in the active site of isocitrate dehydrogenase 1 (IDH1) biologically and diagnostically distinguish low-grade gliomas and secondary glioblastomas from primary glioblastomas. IDH1 mutations lead to the formation of the oncometabolite 2-hydroxyglutarate (2-HG) from the reduction of a-ketoglutarate (a-KG), which in turn facilitates tumorigenesis by modifying DNA and histone methylation as well blocking differentiation processes. Although mutant IDH1 expression is thought to drive the gliomagenesis process, the extent to which it remains a viable therapeutic target remains unknown. To address this question, we exposed immortalized (p53/pRb deficient), untransformed human astrocytes to the mutant IDH1 inhibitor AGI-5198 prior to, concomitant with, or at intervals after, introduction of transforming mutant IDH1, then measured effects on 2-HG levels, histone methylation (H3K4me3, H3K9me2, H3K9me3, or H3K27me3), and growth in soft agar. Addition of AGI-5198 prior to, or concomitant with, introduction of mutant IDH1 blocked all mutant IDH1-driven changes, including cellular transformation. Addition at time intervals as short as 4 days following introduction of mutant IDH1 also suppressed 2-HG levels, but had minimal effects on histone methylation, and lost the ability to suppress clonogenicity in a time-dependent manner. Furthermore, in two different models of mutant IDH1-driven gliomagenesis, AGI-5198 exposures that abolished production of 2-HG also failed to decrease histone methylation, adherent cell growth, or anchorage-independent growth in soft agar over a prolonged period. These studies show although mutant IDH1 expression drives gliomagenesis, mutant IDH1 itself rapidly converts from driver to passenger. Implications: Agents that target mutant IDH may be effective for a narrow time and may require further optimization or additional therapeutics in glioma.",
author = "Johannessen, {Tor Christian Aase} and Joydeep Mukherjee and Pavithra Viswanath and Shigeo Oba and Ronen, {Sabrina M.} and Rolf Bjerkvig and Pieper, {Russell O.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1158/1541-7786.MCR-16-0141",
language = "English",
volume = "14",
pages = "976--983",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

Johannessen, TCA, Mukherjee, J, Viswanath, P, Oba, S, Ronen, SM, Bjerkvig, R & Pieper, RO 2016, 'Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis', Molecular Cancer Research, vol. 14, no. 10, pp. 976-983. https://doi.org/10.1158/1541-7786.MCR-16-0141

Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis. / Johannessen, Tor Christian Aase; Mukherjee, Joydeep; Viswanath, Pavithra; Oba, Shigeo; Ronen, Sabrina M.; Bjerkvig, Rolf; Pieper, Russell O.

In: Molecular Cancer Research, Vol. 14, No. 10, 01.10.2016, p. 976-983.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis

AU - Johannessen, Tor Christian Aase

AU - Mukherjee, Joydeep

AU - Viswanath, Pavithra

AU - Oba, Shigeo

AU - Ronen, Sabrina M.

AU - Bjerkvig, Rolf

AU - Pieper, Russell O.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Missense mutations in the active site of isocitrate dehydrogenase 1 (IDH1) biologically and diagnostically distinguish low-grade gliomas and secondary glioblastomas from primary glioblastomas. IDH1 mutations lead to the formation of the oncometabolite 2-hydroxyglutarate (2-HG) from the reduction of a-ketoglutarate (a-KG), which in turn facilitates tumorigenesis by modifying DNA and histone methylation as well blocking differentiation processes. Although mutant IDH1 expression is thought to drive the gliomagenesis process, the extent to which it remains a viable therapeutic target remains unknown. To address this question, we exposed immortalized (p53/pRb deficient), untransformed human astrocytes to the mutant IDH1 inhibitor AGI-5198 prior to, concomitant with, or at intervals after, introduction of transforming mutant IDH1, then measured effects on 2-HG levels, histone methylation (H3K4me3, H3K9me2, H3K9me3, or H3K27me3), and growth in soft agar. Addition of AGI-5198 prior to, or concomitant with, introduction of mutant IDH1 blocked all mutant IDH1-driven changes, including cellular transformation. Addition at time intervals as short as 4 days following introduction of mutant IDH1 also suppressed 2-HG levels, but had minimal effects on histone methylation, and lost the ability to suppress clonogenicity in a time-dependent manner. Furthermore, in two different models of mutant IDH1-driven gliomagenesis, AGI-5198 exposures that abolished production of 2-HG also failed to decrease histone methylation, adherent cell growth, or anchorage-independent growth in soft agar over a prolonged period. These studies show although mutant IDH1 expression drives gliomagenesis, mutant IDH1 itself rapidly converts from driver to passenger. Implications: Agents that target mutant IDH may be effective for a narrow time and may require further optimization or additional therapeutics in glioma.

AB - Missense mutations in the active site of isocitrate dehydrogenase 1 (IDH1) biologically and diagnostically distinguish low-grade gliomas and secondary glioblastomas from primary glioblastomas. IDH1 mutations lead to the formation of the oncometabolite 2-hydroxyglutarate (2-HG) from the reduction of a-ketoglutarate (a-KG), which in turn facilitates tumorigenesis by modifying DNA and histone methylation as well blocking differentiation processes. Although mutant IDH1 expression is thought to drive the gliomagenesis process, the extent to which it remains a viable therapeutic target remains unknown. To address this question, we exposed immortalized (p53/pRb deficient), untransformed human astrocytes to the mutant IDH1 inhibitor AGI-5198 prior to, concomitant with, or at intervals after, introduction of transforming mutant IDH1, then measured effects on 2-HG levels, histone methylation (H3K4me3, H3K9me2, H3K9me3, or H3K27me3), and growth in soft agar. Addition of AGI-5198 prior to, or concomitant with, introduction of mutant IDH1 blocked all mutant IDH1-driven changes, including cellular transformation. Addition at time intervals as short as 4 days following introduction of mutant IDH1 also suppressed 2-HG levels, but had minimal effects on histone methylation, and lost the ability to suppress clonogenicity in a time-dependent manner. Furthermore, in two different models of mutant IDH1-driven gliomagenesis, AGI-5198 exposures that abolished production of 2-HG also failed to decrease histone methylation, adherent cell growth, or anchorage-independent growth in soft agar over a prolonged period. These studies show although mutant IDH1 expression drives gliomagenesis, mutant IDH1 itself rapidly converts from driver to passenger. Implications: Agents that target mutant IDH may be effective for a narrow time and may require further optimization or additional therapeutics in glioma.

UR - http://www.scopus.com/inward/record.url?scp=84991660847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991660847&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-16-0141

DO - 10.1158/1541-7786.MCR-16-0141

M3 - Article

C2 - 27430238

AN - SCOPUS:84991660847

VL - 14

SP - 976

EP - 983

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 10

ER -